<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02762539</url>
  </required_header>
  <id_info>
    <org_study_id>Omega 3 head injury</org_study_id>
    <nct_id>NCT02762539</nct_id>
  </id_info>
  <brief_title>Omega3 PUFA in Head Trauam</brief_title>
  <acronym>SMOFbrain</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Traumatic brain injury (TBI) is major health problem that stands as a significant cause of
      death and permanent disability. TBI is considered as global public health epidemic. On
      pathophysiologic basis, TBI is described as occurring in two phases, primary and secondary.
      Once a primary insult occurs like trauma or ischemia, the secondary injury begins though main
      four mechanisms; ischemia, brain edema, axonal injury and neuro-inflammation. Omega-3 PUFAs
      (Polyunsaturated fatty acids) are postulated to have neuroregenerative properties with the
      ability to impact all four main mechanisms of the secondary injury Patients will be allocated
      into one of two groups through a random table generation; Control group in which patients
      will follow our local protocol for TBI management without SMOF-lipid infusion. SMOF-lipid
      group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for
      intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive
      oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glasgow coma scale after 48 hour of infusion</measure>
    <time_frame>48 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control group in which patients will follow our local protocol for TBI management without SMOF-lipid infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMOF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMOF-lipid group in which patients will receive 0.5 g/Kg SMOF lipid 10% emulsion (Lipid emulsion for intravenous nutrition containing; 6% soybean oil / 6% medium chain triglycerides / 5% olive oil / 3%fish oil) daily over 12 hours starting once admitted to ICU for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>omega-3 enriched SMOF lipid emusion</intervention_name>
    <arm_group_label>SMOF group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mild to moderate head trauma

        Exclusion Criteria:

          -  sensitivity to SMOF lipid severe head trauama
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mansoura university</name>
      <address>
        <city>Al Manşūrah</city>
        <state>Dkahleya</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alreafey Kandeel, MD</last_name>
      <phone>00201008158591</phone>
      <email>refa3ey2@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2016</study_first_submitted>
  <study_first_submitted_qc>May 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2016</study_first_posted>
  <last_update_submitted>November 25, 2017</last_update_submitted>
  <last_update_submitted_qc>November 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>AlRefaey Kandeel</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

